default author photo

Sabrina Chiara Cecere

Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Uro-Gynecological Medical Oncology

SCHOLARLY PAPERS

3

DOWNLOADS

218

TOTAL CITATIONS

0

Scholarly Papers (3)

1.

MITO END-3: A Randomized Phase II Trial of Avelumab Plus Carboplatin and Paclitaxel Compared to Carboplatin and Paclitaxel in Advanced or Recurrent Endometrial Cancer

Number of pages: 32 Posted: 27 Dec 2022
Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Uro-Gynecological Medical Oncology, Catholic University of the Sacred Heart, Rome - Gynecologic Oncology Unit, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Clinical Trial Unit, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Clinical Trial Unit, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Uro-Gynecological Medical Oncology, Centro di Riferimento Oncologico - Medical Oncology and Oncological Prevention Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST) - Clinical and Experimental Oncology Unit, Azienda Sanitaria Universitaria Friuli Centrale - Oncology Department, “Senatore Antonio Perrino” Hospita - Medical Oncology Unit, Baylor University - Lester and Sue Smith Breast Center, Oncology Unit, “S. Vincenzo” Hospital, S. Maria delle Croci Hospital - Oncology Unit, Infermi Hospital - Medical Oncology Unit, Mater Salutis Hospital AULSS9, “Scaligera” - Medical Oncology Unit, Medical Oncology Unit “Santo Stefano” Hospital, Niguarda Ca' Granda Hospital - Oncology Unit, IRCCS Ospedale Policlinico San Martino - U.O. Clinica di Oncologia Medica, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Uro-Gynecological Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS - Department of Woman, Child and Public Health, Centro di Riferimento Oncologico - Medical Oncology and Oncological Prevention Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST) - Clinical and Experimental Oncology Unit, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Uro-Gynecological Medical Oncology, Catholic University of the Sacred Heart, Rome - Gynecologic Oncology Unit, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Clinical Trial Unit, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Microenvironment Molecular Targets Unit, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Microenvironment Molecular Targets Unit, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Microenvironment Molecular Targets Unit, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Pathological Anatomy and Cytopathology Unit, University of Campania “Luigi Vanvitelli” - Medical Statistics and Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Clinical Trial Unit
Downloads 126 (572,948)

Abstract:

Loading...

Endometrial Cancer, First-line treatment, Chemotherapy, Avelumab

2.

Benefit from the Immune Checkpoint Inhibitor Atezolizumab Addition in Poor Prognostic Ovarian Cancer Patients : Imagyn050 Trial

Number of pages: 20 Posted: 11 Feb 2025
Université Lyon 1 - Faculty of Medicine Lyon-Sud, affiliation not provided to SSRN, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Uro-Gynecological Medical Oncology, Université de Lyon - Université Claude Bernard Lyon 1, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Koc University - School of Medicine, Memorial Sloan Kettering Cancer Center, affiliation not provided to SSRN, Mount Sinai Health System - Icahn School of Medicine, University of Turin, Siteman Cancer Center, Japanese Foundation for Cancer Research, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Alabama at Birmingham, affiliation not provided to SSRN, Hospital Universitari Son Espases and University of Oklahoma - Stephenson Cancer Center
Downloads 65 (916,100)

Abstract:

Loading...

Ovarian Neoplasms, Immune checkpoint inhibitors, atezolizumab [Supplementary Concept], CA-125 antigen, Prognosis

3.

Adverse Events in the Placebo Arm of Solo2/Engot-Ov21 Maintenance Trial of Olaparib in Recurrent Ovarian Cancer

Number of pages: 27 Posted: 24 Sep 2024 Last Revised: 01 May 2025
The University of Sydney, The University of Sydney, The University of Sydney - NHMRC Clinical Trials Centre, Université de Caen, University College London - UCL Cancer Institute, Harvard University - Harvard Medical School, University of Toronto - University Health Network, Tel Aviv University, affiliation not provided to SSRN, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Uro-Gynecological Medical Oncology, affiliation not provided to SSRN, affiliation not provided to SSRN, Saitama Medical University International Medical Center (SIMC), affiliation not provided to SSRN, affiliation not provided to SSRN, ARCAGY-GINECO and The University of Sydney
Downloads 27 (1,359,097)

Abstract:

Loading...

Placebo, adverse events, trial design, ovarian cancer, maintenance therapy, PARPi